MBX Biosciences Inc. (MBX) said that it has priced its initial public offering of 10.20 million shares of its common stock at $16.00 per share.
The company noted that it expects gross proceeds from the offering, before deducting the underwriting discounts and commissions and offering expenses, to be $163.2 million.
In addition, MBX Biosciences has granted the underwriters a 30-day option to buy an additional 1.53 million shares of its common stock at the initial public offering price, less underwriting discounts and commissions.
The shares are expected to begin trading on the Nasdaq Global Select Market on September 13, 2024 under the ticker symbol "MBX." The offering is expected to close on September 16, 2024.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.